CTOs on the Move

Institutional Pharmacy Solutions

www.ipspharmacy.com

 
Institutional Pharmacy Solutions is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ipspharmacy.com
  • 400 Interstate Park Dr Ste 422
    Montgomery, AL USA 36109
  • Phone: 334.819.4500

Executives

Name Title Contact Details

Similar Companies

EIP Pharma

EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.

Alkermes

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

Kane Veterinary Supplies

Kane Veterinary Supplies Ltd. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blaine Labs

Blaine Labs is a Santa Fe Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.